Excellent
Aligned
Patient Risk:
Low
Summary
The response’s HBV reactivation, testing (HBsAg and anti-HBc), and monitoring during and after HARVONI treatment claims are directly supported by the provided label excerpts (Sections 5.1, 2.1, and 17) with no contradictions.
Category Scores
Accurate Statements
HBV reactivation can occur in patients coinfected with HBV during or after HARVONI treatment, including in patients with current (HBsAg-positive) and resolved HBV infection (HBsAg-negative, anti-HBc-positive).
Section 5.1: reports in HCV/HBV coinfected patients not receiving HBV antiviral therapy; includes HBsAg-positive and resolved infection.
All patients should be tested for evidence of current or prior HBV infection before initiating HARVONI using HBsAg and anti-HBc.
Section 2.1 and Section 5.1: test all patients with HBsAg and anti-HBc prior to initiating HCV treatment with HARVONI.
Patients with serologic evidence of HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HARVONI treatment and during post-treatment follow-up.
Section 5.1: monitor during treatment and during post-treatment follow-up; initiate appropriate management as clinically indicated.
Patient counseling should include that HBV reactivation can occur in HBV-coinfected patients during or after treatment.
Section 17 patient counseling information.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response reflects label-consistent risk communication and required testing/monitoring steps for HBV reactivation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Aligned
Primary Issue
Suggested Improvement